bankrx
- The U.S. FDA has issued a warning letter to Sanofi (NASDAQ:SNY) regarding Current Good Manufacturing Practices violations at a Genzyme plant in Framingham, Mass.
- The document accuses the drugmaker of making active pharmaceutical ingredients that are adulterated.
- Agency officials inspected